Glenmark Pharmaceuticals Ltd.
Snapshot View

596.60 +0.50 ▲0.1%

05 August 2021, 01:35:00 P.M.
Volume: 71,003

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.glenmarkpharma.com
Financial Indicators
Market Cap 16,820.04 Cr.
Earnings per share (EPS) 34.38 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 17.34 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 250.37 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.38 Calculated using Price: 596.10
Dividend Yield 0.42 Period Ending 2020-03
No. of Shares Subscribed 28.22 Cr. 282,168,156 Shares
FaceValue 1
Company Profile

Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.

India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.

Business area of the company

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Awards

  • It was conferred with the Pharmaexcil Gold Award for New Chemical Entities 2015.
  • SCRIP crowned Glenmark as the ‘Best Pharma Company in Emerging markets’ and ‘Best Overall Pipline’ at SCRIP Awards 2011 in London. 
  • Swiss Ambassador's award for Exceptional Innovation - 2012.
  • It received the Bombay Chamber of Commerce and Industry Civic Award 2014. 
  • It was conferred with the prestigious Golden Peacock Management Award - 2015 for its Environment Sustainability initiatives at the Goa manufacturing facility.

Milestone

2010

  • Glenmark Pharmaceuticals has entered into a settlement and license agreement with Sepracor Inc to market generic Eszopiclone tablets.

2012

  • Forest Laboratories and Glenmark Sign Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions.

2014 

  • Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitor.

2015

  • Glenmark announced the Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. In the same year, Glenmark received approval for generic Seretide in Russia.

2016 

  • Glenmark launched ezetimibe, the first and only generic version of Zetia in the United States for the treatment of high cholesterol.

2019

  • Glenmark Pharmaceuticals and Mankind Pharmaceuticals have inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
  • Glenmark Pharmaceuticals’ partner -- Seqirus Pty (Seqirus) has received marketing approval for Ryaltris from the Therapeutic Goods Administration (TGA), Australia.

2020

  • Glenmark Pharmaceuticals has launched NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.
  • Glenmark Pharmaceuticals has launched the world’s first hypertension awareness symbol, in collaboration with Association of Physicians of India (API) and Hypertension Society of India (HSI). 
  • Glenmark Pharmaceuticals has launched of a Single Inhaler Triple Therapy AIRZ-FF.
  • Glenmark Pharmaceuticals has entered into an agreement with Hindustan Unilever (HUL) for divestment of its VWash brand and other extensions.
  • Glenmark Pharmaceuticals’ Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma) for commercializing its novel nasal spray Ryaltris in the US.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.08%
1 Week
+0.85%
1 Month
-9.87%
3 Month
+4.05%
6 Month
+18.50%
1 Year
+33.24%
2 Year
+44.67%
5 Year
-29.22%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 20.92 24.33 18.99 8.79 27.46 27.31 16.67 17.21 13.32
Return on Capital Employed (%) 14.44 17.67 15.04 12.40 18.53 20.54 14.77 16.47 14.04
Return on Assets (%) 9.01 10.40 7.51 2.58 8.52 11.33 7.40 7.98 6.17

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2,402 2,763 2,983 1,783 3,630 4,493 5,163 5,605 6,071
Non Curr. Liab. 1,138 1,625 1,967 2,749 1,499 3,258 2,824 2,280 3,033
Curr. Liab. 1,902 2,201 2,949 3,777 3,999 2,703 3,288 4,021 4,126
Minority Int. 25 24 13 0 0 0 0 0 0
Equity & Liab. 5,466 6,614 7,912 8,309 9,128 10,453 11,275 11,906 13,229
Non Curr. Assets 2,519 2,887 3,150 2,978 3,224 3,578 4,286 5,209 6,425
Curr. Assets 2,947 3,727 4,763 5,331 5,904 6,875 6,989 6,697 6,804
Misc. Exp. not W/O
Total Assets 5,466 6,614 7,912 8,309 9,128 10,453 11,275 11,906 13,229

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 4,021 4,969 5,945 6,681 7,562 9,079 9,074 9,865 10,641
Other Income 18 11 11 7 20 37 91 208 160
Total Income 4,039 4,980 5,956 6,688 7,582 9,117 9,166 10,074 10,801
Total Expenditure -3,306 -3,954 -4,854 -5,467 -6,125 -7,043 -7,459 -8,280 -8,943
PBIDT 733 1,026 1,102 1,221 1,457 2,074 1,707 1,794 1,858
Interest -147 -160 -189 -190 -179 -237 -286 -335 -377
Depreciation -98 -127 -217 -300 -234 -264 -302 -326 -417
Taxation -24 -111 -151 -334 -301 -383 -315 -376 -320
Exceptional Items -187 -81 167 33
PAT 464 628 546 209 743 1,109 804 925 776

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 804 648 854 482 345 657 1,648 1,324 1,392
Cash Fr. Inv. -278 -464 -368 -540 -880 -712 -1,013 -699 -784
Cash Fr. Finan. -361 195 -98 199 699 543 -469 -739 -445
Net Change 165 379 388 141 163 488 166 -114 164
Cash & Cash Eqvt 320 605 795 764 857 1,056 1,233 936 1,110

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 46.58 46.58 46.59 46.62 46.62 46.63 46.63 46.63 46.63
Public 53.42 53.42 53.41 53.38 53.38 53.37 53.37 53.37 53.37
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 03 Aug 2021
Initial Public Offering ('Offer') Of Equity Shares Of Our Wholly Owned Subsidiary 'Glenmark Life Sciences Limited'
This is further to our intimations dated April 16 2021 and July 20 2021 regarding the submission of the draft red herring prospectus dated April 16 2021 (DRHP) with the Securities and Exchange Board of India and filing of the red herring prospectus dated July 19 2021 with the Registrar of Companies Pune at Maharashtra (ROC) by our wholly owned subsidiary Glenmark Life Sciences Limited. We would like to inform you of the following:
a. The IPO comprised of a fresh issue of 14 722 222 equity shares by Glenmark Life Sciences Limited and an offer for sale of 6 300 000 equity shares by the Company. The IPO opened for subscription on July 27 2021 and closed on July 29 2021.
b. Glenmark Life Sciences Limited filed the prospectus with the ROC on July 30 2021.
c. The equity shares of the Glenmark Life Sciences Limited pursuant to the IPO were allotted at an offer price of Rs. 720 per equity share to the successful bidders on August 3 2021.
Mon, 02 Aug 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets
Tue, 20 Jul 2021
Filing And Approval Of The Red Herring Prospectus ('RHP') Dated July 19 2021 Of Our Wholly Owned Subsidiary 'Glenmark Life Sciences Limited' In Connection With Its Proposed Initial Public Offering Of Equity Shares ('Offer' Or 'IPO')
Further to our intimation dated April 16 2021 regarding submission of the draft red herring prospectus dated April 16 2021 (DRHP) with the Securities and Exchange Board of India by our wholly owned subsidiary Glenmark Life Sciences Limited please be informed that on July 19 2021 Glenmark Life Sciences Limited had filed the RHP with the Registrar of Companies Pune at Maharashtra (ROC) in connection with the Offer. The RHP has been taken on record by the ROC on July 20 2021.

Technical Scans View Details

Wed, 04 Aug 2021
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week High Zone Close Within 52 Week High Zone
William %R Crossed -80 From Above William %R Crossed -80 From Above
Tue, 03 Aug 2021
Close Within 52 Week High Zone Close Within 52 Week High Zone
CCI Bullish CCI Bullish

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 788.65 +0.4%
Divi's Laboratories Ltd. 131,785.24 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,789.80 +0.4%
Cipla Ltd. 75,796.16 947.50 +0.8%
Cadila Healthcare Ltd. 60,170.47 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,062.95 -0.1%
Piramal Enterprises Ltd. 57,915.28 2,593.75 +1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 31.52 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,593.75 +1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 4.15 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,593.75 +1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 0.10 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,593.75 +1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 14.13 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,593.75 +1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 17.85 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,593.75 +1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 19,159.59 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,593.75 +1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 788.65 +0.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,941.00 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,789.80 +0.4%
Cipla Ltd. Consolidated 2021-03 2,401.30 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 586.50 -0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,062.95 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,593.75 +1.7%